🇺🇸 ABBV — AbbVie Inc.

Salud Compra
← Volver

Precio actual

291,31 USD

Máx. histórico

294,89

7 días

Caída desde máximo

-1,21%

Rango 52 semanas

190,75 – 302,93

Variación hoy

+1,07%

Cierre anterior

288,24

Rango de hoy

281,07 – 291,73

Volumen hoy

5.017.683

Peor caída histórica

-45,09%

26/01/2018 → 15/08/2019

Recuperado en 477 días

Volatilidad anualizada ⓘ

26,30%

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
50,05 (puede no estar actualizado)
Dividend yield
2,40% (puede no estar actualizado)
Precio objetivo analistas
306,42 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,9200 USD · Yield: 2,38%
Fecha de pago Importe por participación
12/01/2023 1,4800 USD
13/10/2022 1,4100 USD
14/07/2022 1,4100 USD
13/04/2022 1,4100 USD
13/01/2022 1,4100 USD
14/10/2021 1,3000 USD
14/07/2021 1,3000 USD
14/04/2021 1,3000 USD
14/01/2021 1,3000 USD
14/10/2020 1,1800 USD
14/07/2020 1,1800 USD
14/04/2020 1,1800 USD
14/01/2020 1,1800 USD
11/10/2019 1,0700 USD
12/07/2019 1,0700 USD
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
16/08/2023 152,59 153,60 151,38 151,55 -0,37% 1,45% 3.214.900
15/08/2023 151,57 152,90 150,79 152,12 -0,10% 1,39% 3.636.300
14/08/2023 153,02 153,14 151,57 152,27 +0,06% 1,03% 2.570.900
11/08/2023 151,95 153,50 151,72 152,18 +0,49% 1,17% 3.454.800
10/08/2023 151,20 152,84 150,57 151,44 +0,44% 1,50% 3.275.800
09/08/2023 150,49 152,06 149,91 150,77 +0,77% 1,43% 3.737.100
08/08/2023 150,78 151,75 148,92 149,62 -0,47% 1,88% 4.013.400
07/08/2023 148,00 150,88 147,80 150,33 +1,76% 2,08% 3.800.600
04/08/2023 148,97 150,57 147,16 147,73 -0,89% 2,29% 4.231.200
03/08/2023 148,96 149,36 148,18 149,05 -0,22% 0,79% 4.674.300
02/08/2023 148,11 150,57 148,11 149,38 +0,57% 1,66% 5.756.400
01/08/2023 150,00 150,87 147,84 148,54 -0,70% 2,02% 4.409.600
31/07/2023 150,43 150,50 147,62 149,58 -0,84% 1,91% 9.109.200
28/07/2023 149,92 151,76 148,56 150,85 +1,34% 2,13% 8.000.300
27/07/2023 144,48 151,37 144,48 148,85 +4,90% 4,77% 13.664.400
26/07/2023 141,43 142,28 140,52 141,90 +0,19% 1,24% 5.006.800
25/07/2023 142,40 142,93 141,32 141,63 -1,08% 1,13% 4.778.200
24/07/2023 143,10 144,43 142,84 143,18 -0,39% 1,11% 4.468.700
21/07/2023 142,20 144,18 141,94 143,74 +1,09% 1,58% 5.654.300
20/07/2023 138,84 142,72 138,55 142,19 +3,28% 3,00% 7.009.800
19/07/2023 137,24 138,06 136,95 137,68 +0,81% 0,81% 4.784.200
18/07/2023 134,80 137,90 134,71 136,58 +1,30% 2,37% 5.392.800
17/07/2023 135,82 136,23 134,56 134,83 -0,87% 1,23% 4.033.000
14/07/2023 134,73 136,62 134,12 136,01 +1,81% 1,86% 5.544.100
13/07/2023 132,93 134,10 132,70 133,59 -1,03% 1,05% 4.631.800
12/07/2023 135,82 136,60 134,79 134,98 -0,44% 1,33% 4.944.100
11/07/2023 134,00 135,76 133,68 135,57 +0,80% 1,55% 5.144.800
10/07/2023 135,41 136,09 134,06 134,49 -0,75% 1,50% 5.153.300
07/07/2023 137,15 137,65 135,35 135,50 -1,28% 1,68% 6.873.200
06/07/2023 137,48 138,28 136,44 137,25 -0,27% 1,34% 6.091.000